Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene.

BACKGROUND Overexpression of human lecithin-cholesterol acyltransferase (LCAT) in transgenic mice results in an increase of the antiatherogenic HDLs. METHODS AND RESULTS To investigate the potential use of LCAT for gene therapy, a recombinant adenovirus was constructed in which the human LCAT cDNA was expressed under the control of the human cytomegalovirus immediate/early promoter followed by a chimeric intron (AdCMV human LCAT). Human apolipoprotein (apo) A-I transgenic mice infected with AdCMV human LCAT by intravenous injection accumulated reactive LCAT in the plasma. LCAT activity was increased 201-fold in the plasma of mice infected with 1 x 10(6) pfu AdCMV human LCAT, from 45 +/- 2 to 9068 +/- 812 nmol.mL-1.h-1, in comparison with basal LCAT activity measured in control mice, 5 days after injection. Plasma HDL cholesterol levels rose from 117 +/- 12 to 797 +/- 48 mg/dL, and plasma human apo A-I concentrations increased from 247 +/- 14 to 616 +/- 17 mg/dL, in AdCMV human LCAT infected mice compared with control mice. HDL particles were larger and had a different electrophoretic mobility. Studies of cholesterol efflux by incubation of serum with cholesterol-loaded Fu5AH cells showed that serum from AdCMV human LCAT-infected mice promoted a significantly higher efflux than did that of the controls. CONCLUSIONS These data establish the potential of this approach for treatment of subjects with LCAT gene defects as well as patients with low plasma levels of apo A-I and HDL cholesterol.

[1]  H. Brewer,et al.  Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. , 1996, The Journal of clinical investigation.

[2]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[3]  M. Perricaudet,et al.  Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit , 1996, Journal of virology.

[4]  A. Tall,et al.  Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI. , 1995, The Journal of clinical investigation.

[5]  P. Denéfle,et al.  Section Review: Cardiovascular & Renal: Genetic therapies for vascular diseases and lipid disorders , 1995 .

[6]  E. Rubin,et al.  Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism. , 1995, The Journal of clinical investigation.

[7]  M. Liu,et al.  Specificity of lecithin:cholesterol acyltransferase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species. , 1995, Journal of lipid research.

[8]  W. J. Johnson,et al.  Effects of Acceptor Particle Size on the Efflux of Cellular Free Cholesterol (*) , 1995, The Journal of Biological Chemistry.

[9]  G. Luc,et al.  Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. , 1995, European journal of biochemistry.

[10]  R. F. Hoyt,et al.  Overexpression of Human Lecithin Cholesterol Acyltransferase Leads to Hyperalphalipoproteinemia in Transgenic Mice (*) , 1995, The Journal of Biological Chemistry.

[11]  S. Yokoyama,et al.  Lecithin:cholesterol acyltransferase reaction on cellular lipid released by free apolipoprotein-mediated efflux. , 1995, Biochemistry.

[12]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[13]  D. Rader,et al.  Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. , 1995, European journal of biochemistry.

[14]  P. Giral,et al.  A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[15]  S. Eisenberg,et al.  Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  J. Rosenblatt,et al.  Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes , 1994, Molecular and cellular biology.

[17]  M C Phillips,et al.  The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins. , 1994, The Journal of biological chemistry.

[18]  D. Rader,et al.  Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. , 1994, The Journal of clinical investigation.

[19]  H. Arai,et al.  Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. , 1993, The Journal of biological chemistry.

[20]  H. Klein,et al.  Fish eye syndrome: a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis. , 1993, The Journal of clinical investigation.

[21]  Y. Marcel,et al.  Cholesterol efflux from fibroblasts to discoidal lipoproteins with apolipoprotein A-I (LpA-I) increases with particle size but cholesterol transfer from LpA-I to lipoproteins decreases with size. , 1993, Biochemistry.

[22]  D. Rader,et al.  Two different allelic mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in classic LCAT deficiency: LCAT (tyr83-->stop) and LCAT (tyr156-->asn). , 1993, Journal of lipid research.

[23]  S. Kunitake,et al.  Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. , 1992, Journal of lipid research.

[24]  M. Perricaudet,et al.  Widespread long-term gene transfer to mouse skeletal muscles and heart. , 1992, The Journal of clinical investigation.

[25]  A. Jonas.  Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. , 1991, Biochimica et biophysica acta.

[26]  S. Eisenberg,et al.  Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. , 1991, The Journal of clinical investigation.

[27]  R. Krauss,et al.  Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  F. Karpe,et al.  Studies on the lecithin: cholesterol acyltransferase substrate properties of HDL as determined by its subclass distribution analysed by gradient gel electrophoresis. , 1990, Biochimica et biophysica acta.

[29]  J. Auwerx,et al.  Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine. , 1989, Journal of lipid research.

[30]  S. Eisenberg,et al.  Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. , 1989, The Journal of clinical investigation.

[31]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .

[32]  C. Fielding,et al.  Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. , 1988, Biochemistry.

[33]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[34]  R. Krauss,et al.  Nondenaturing polyacrylamide gradient gel electrophoresis. , 1986, Methods in enzymology.

[35]  J. Albers,et al.  Interspecies activation of lecithin-cholesterol acyltransferase by apolipoprotein A-I isolated from the plasma of humans, horses, sheep, goats and rabbits. , 1983, Biochimica et biophysica acta.

[36]  J. Albers,et al.  Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin: cholesterol acyltransferase activity. , 1982, Journal of lipid research.

[37]  C. Fielding,et al.  Regulation of human plasma lecithin:cholesterol acyltransferase activity by lipoprotein acceptor cholesteryl ester content. , 1981, The Journal of biological chemistry.

[38]  C. Fielding,et al.  A protein cofactor of lecithin:cholesterol acyltransferase. , 1972, Biochemical and biophysical research communications.

[39]  K. Norum,et al.  Determination of lecithin: cholesterol acyltransfer in human blood plasma. , 1971, Scandinavian journal of clinical and laboratory investigation.

[40]  J. Glomset,et al.  The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.

[41]  H. Bergmeyer.  Methods of Enzymatic Analysis , 2019 .